Opthea Announces Launch of Proposed Initial Public Offering in the United States
October 11, 2020 20:00 ET
|
Opthea Limited
MELBOURNE, Australia, Oct. 11, 2020 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive...
Opthea to Appoint Dr Jeremy Levin as Chairman of the Board
October 05, 2020 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive...
Opthea Files Registration Statement for Proposed Initial Public Offering in the United States
September 25, 2020 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive...
Opthea Appoints US-Based Non-Executive Director
September 10, 2020 12:04 ET
|
Opthea Limited
MELBOURNE, Australia, Sept. 10, 2020 (GLOBE NEWSWIRE) -- The directors of Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent...
Opthea Announces Plans to Conduct Registered Public Offering and Listing in the United States
August 24, 2020 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT) today announces that it has confidentially submitted a draft registration statement on Form F-1 to the U.S....
Opthea Completes Successful Meetings with FDA and EMA for OPT-302 Phase 3 Clinical Program in Wet AMD
August 21, 2020 05:30 ET
|
Opthea Limited
Regulatory engagement provides clear pathway through Phase 3 to support filing for marketing approvals in US and EuropeRegulatory agreement of using Lucentis® and Eylea® in combination with OPT-302...
Opthea to Host Wet AMD and DME Key Opinion Leader Symposium on August 5, 2020 (EDT)
July 28, 2020 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, July 28, 2020 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive...
Opthea Reports New Data of OPT-302 in Diabetic Macular Edema at the 2020 Annual Meeting of the American Society of Retina Specialists
July 27, 2020 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, July 27, 2020 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive...
Opthea Clinical Data of OPT-302 in Diabetic Macular Edema to be Presented at American Society of Retina Specialists 2020 Annual Meeting
July 23, 2020 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, July 23, 2020 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive...
Opthea Reports Positive Phase 2a Trial Results of OPT-302 in Diabetic Macular Edema
June 09, 2020 19:23 ET
|
Opthea Limited
Primary endpoint of response with OPT-302 + Eylea® (aflibercept) achieved: 52.8% of refractory DME patients gained ≥ 5 letters of visual acuity at week 12 following OPT-302 combination therapy ...